A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
The purpose of the study is to test the effect of rovalpituzumab tesirine in the frontline treatment of small cell lung cancer (SCLC).
Small Cell Lung Cancer
DRUG: Rovalpituzumab Tesirine|DRUG: Cisplatin|DRUG: Etoposide
Dose limiting toxicities (DLT) of rovalpituzumab tesirine when administered as monotherapy, in series or in combination with frontline chemotherapy to subjects with DLL3 expressing extensive-stage small cell lung cancer (SCLC), For Phase 1a, within 21 days after first dose of rovalpituzumab tesirine|Treatment emergent adverse events (TEAEs), For Phase 1a, through 30 days after last dose of study treatment|Incidence of subjects with CTCAE Grade >2 laboratory abnormalities, For Phase 1a, through 30 days after last dose of study treatment|Progression-Free Survival (PFS), For Phase 1b, 4 years
Best overall response rate, 4 years|Duration of response (DOR), 4 years|Clinical Benefit Rate (CBR), 4 years|Overall Survival (OS), 4 years|Incidence of anti-therapeutic antibodies (ATAs) against rovalpituzumab tesirine, 4 years|Progression-free survival (Phase 1a), 4 years|Pharmacokinetic parameters: Cmax (Maximum plasma concentration observed ), 4 years|Pharmacokinetic parameters: AUC0-tau (Area under the plasma concentration-time curve within a dosing interval), 4 years|Pharmacokinetic parameters: AUC0-âˆž (Area under the curve from time 0 extrapolated to infinity), 4 years|Pharmacokinetic parameters: Tmax (Time of Cmax), 4 years|Pharmacokinetic parameters: Ctrough (Observed plasma concentrations at trough), 4 years|Pharmacokinetic parameters: T1/2 (Terminal half-life), 4 years|Pharmacokinetic parameters: CL (Clearance), 4 years|Pharmacokinetic parameters: Vss (Volume of distribution at steady state), 4 years|Incidence of TEAEs, For Phase 1b, 4 years|Changes in vital signs (Heart Rate), 4 years|Changes in vital signs (Blood pressure), 4 years|Changes in vital signs (Temperature), 4 years|Changes in vital signs (Weight), 4 years|Changes in vital signs (Respirations), 4 years|Eastern Cooperative Oncology Group (ECOG) score, 4 years
The purpose of the study is to test the effect of rovalpituzumab tesirine in the frontline treatment of small cell lung cancer (SCLC).